Synonym of ICGi016-A
iTaf9-11
ICAGi001-A
General
Donor Information
General Donor Information |
|
Sex | female |
Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Family history | de novo |
Is the medical history available upon request? | yes, Research Institute of Medical Genetics, TNMRC |
Is clinical information available? | yes, Research Institute of Medical Genetics, TNMRC |
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
arr[GRCh38] 2p25.3(42444_2684871)x1 dn, 2p25.3-p23.3(2771354_24258056)x3 dn
Karyotyping method:
Array CGH
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
BioSamples | SAMEA5230332 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Has the donor agreed to be re-contacted? | Unknown |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | The study was approved by the Scientific Ethics Committee of Research Institute of Medical Genetics, Tomsk NRMC |
Approval number | protocol number 106/2017 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | The study was approved by the Scientific Ethics Committee of Research Institute of Medical Genetics, Tomsk NRMC |
Approval number | protocol number 106/2017 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type | |
Passage number reprogrammed | 5 |
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Lentivirus) |
Genes | |
Is the used vector excisable? |
No |
Absence of reprogramming vector(s)? |
No |
Reprogramming vectors silenced? |
Unknown |
Vector map | |
Vector free reprogramming |
|
Other |
|
Selection criteria for clones | morphology marker expression |
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Gelatin | ||||||
Feeder cells |
mouse embryonic fibroblasts Cellfinder Ont Id: EFO_0004040 |
||||||
Passage method | Mechanically | ||||||
CO2 Concentration | 5 % | ||||||
Medium |
Other medium:
Base medium: DMEM/F12
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
||||||
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
||||||
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
||||||
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
TRA 1-60 |
Yes |
|
||||
SSEA-3 |
Yes |
|
Score:
Marker | Present | Absent |
mCpG | ||
OCT4 |
Differentiation Potency
In vitro spontaneous differentiation
In vitro spontaneous differentiation
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.